Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PREP | P48147 | 3/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190565 | 1.00 | SPHK2 (0.54) | SPHK2SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL80752 | 1.00 | SPHK2 (0.54) | SPHK2SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL7561453 | 0.99 | SPHK2 (0.53) | SPHK2SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL4602602 | 0.96 | SPHK2 (0.58) | SPHK2SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL5267939 | 0.96 | SPHK2 (0.58) | SPHK2SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL809494 | 0.96 | SPHK2 (0.58) | SPHK2SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL4186350 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL6252758 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL4186357 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL7598366 | 0.90 | TMEM97 (0.51) | SMN1; SMN2NPC1RAB9APREPFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| WO-2023187760-A1 | MANNOSE-TARGETED COMPOSITIONS | GENEVANT SCIENCES GMBH (CH) | 2023-10-05 | — | — | WO | disclosed |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | ARBUTUS BIOPHARMA CORPORATION (US) | 2022-06-02 | — | — | US | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| EP-2776430-B1 | 2- (1,2,3-TRIAZOL-2-YL) BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL) PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-9150566-B2 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2776430-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-09-17 | — | — | EP | disclosed |
| WO-2008125570-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125570-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| CN-1688527-A | Fused benzene derivatives and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SPHK2 367/4885SMN1; SMN2 3784/4885NPC1 1218/4885 |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | SPHK2 3364/4885SMN1; SMN2 2277/4885NPC1 345/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | SPHK2 4209/4885SMN1; SMN2 4057/4885NPC1 3378/4885 |
| US-20220168430-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | HAVCR2, HDGF, FABP1 | SPHK2 866/4885SMN1; SMN2 3252/4885NPC1 328/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | SPHK2 140/4885SMN1; SMN2 3686/4885NPC1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.